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Abstract The optimal frequency of intravenous (IV)
bisphosphonate administration is unclear. We thus per-
formed a study evaluating the effects of switching from
3–4 to 12 weekly therapy in patients with biochemically
defined low-risk bone metastases. Patients with serum
C-telopeptide (CTx) levels B600 ng/L after C3 months of
3–4 weekly IV pamidronate were switched to 12 weekly
therapy for 48 weeks. Primary endpoint was the proportion
of patients maintaining CTx levels in the lower-risk range.
All endpoints (serum CTx and bone-specific alkaline
phosphatase (BSAP), skeletal-related events (SREs) and
self-reported pain) were measured at baseline, 6, 12, 24, 36
and 48 weeks. Treatment failure was defined as biochem-
ical failure (CTx [ 600 ng/L) or a SRE. Exploratory bio-
markers including; serum TGF-b, activin-A, bone
sialoprotein (BSP), procollagen type 1 N-terminal pro-
peptide and urinary N-telopeptide (NTx) were assessed at
baseline as predictors for failure to complete treatment.
Seventy-one patients accrued and 43 (61 %) completed
48 weeks of de-escalated therapy. Reasons for failure to
complete treatment included; biochemical failure
(CTx [ 600 ng/L) (n = 10, 14.1 %), on-study SRE
(n = 9, 12.7 %), disease progression (n = 7, 9.9 %
including death from disease [n = 1, 1.4 %]) or patient
choice (n = 2, 2.8 %). Elevated baseline levels of CTx,
BSAP, NTx and BSP were associated with treatment fail-
ure. The majority of patients in this biochemically defined
low-risk population could switch from 3–4 weekly to 12
weekly bisphosphonate therapy with no effect on CTx
levels or SREs during the 48 week study. Larger trials are
required to assess the roles of biomarkers as predictors of
adequacy of de-escalated therapy.
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Background
Bisphosphonates are administered every 3–4 weeks to
patients with bone metastases from breast cancer, based on
experience in treating hypercalcaemia of malignancy [1] as
well as for convenience (coinciding with the timing of most
chemotherapy regimens). However, this rationale ignores
both the pharmacodynamics of bone-targeted agents which
have activity in bone for many years [2] and the modest
absolute magnitude of benefit from these therapies [3]. In
addition, once started bone-targeted agents are rarely dis-
continued [4–6] and are usually given for longer than the
1–2 years evaluated in clinical trials [7–9]. As patients with
metastases limited to the skeleton may have a prolonged
disease course [5, 7, 10, 11], they will receive multiple
doses of bisphosphonate [12]. This is important as adverse
events such as renal toxicity [13], osteonecrosis of the jaw
(ONJ) and atypical fractures [14–16], are associated with
both the potency and the cumulative administered dose
[17]. Frequent therapy also has financial and quality of life
implications for patients and health care providers [18].
A number of completed or ongoing trials [19–25] have
evaluated the safety and efficacy of reduced dosing inter-
vals of bisphosphonates. However, use of skeletal related
events (SREs), defined as pathological fractures, radio-
therapy/surgery to bone, spinal cord compression or hy-
percalcaemia as the primary study endpoint [19], requires a
large sample size and extended follow up. Consequently,
smaller studies have utilised biomarkers of bone resorption,
such as, N- and C-telopeptides (NTx and CTx respectively)
as surrogate markers of SRE risk [26–28].
In a small pilot randomised study comparing 3–4 weekly
with 12 weekly pamidronate in patients with biochemically
defined low-risk disease, we successfully demonstrated
similar control of serum CTx between the two study arms
with 72 % of patients maintaining control of CTx in the de-
escalated arm [20]. Here, we report on a larger cohort of
de-escalated (every 12 weeks) bisphosphonate therapy in
patients with biochemically defined low-risk bone disease.
It was hypothesized that de-escalated therapy will provide
similar control of bone resorption for a period of 1 year in
these lower risk patients. In addition, through the pro-
spective collection of serum and urine samples, we eval-




Women with breast cancer and radiologic, scintigraphic,
and/or biopsy confirmed bone metastases who had received
at least 3 months of 3–4 weekly IV pamidronate were
enrolled. Eligible women needed to have evidence of
lower-risk metastatic bone disease defined as baseline
serum CTx \ 600 ng/L. This threshold was selected based
on data from large prospective datasets [26], demonstrating
that it is indicative of the range between low and medium
risk disease. Patients were to have had no change in sys-
temic anti-cancer therapy or radiation therapy in the
28 days prior to signing consent [21]. The study was
approved by the Ontario Cancer Research Ethics Board,
Toronto, Canada. As part of the main study consent,
patients could also optionally consent to the collection of
urine and serum samples for future research.
Trial design
All study participants were switched from 3–4-weekly to
12 weekly pamidronate. Baseline levels of fasting serum
CTx and bone-specific alkaline phosphatase (BSAP),
parathyroid hormone (PTH) and 25-hydroxyvitamin D
were measured. Serum CTx and BSAP were reassessed at
weeks 6, 12, 24, 36 and 48. Data on self-reported pain
using the Brief Pain Inventory (BPI) [29], the Functional
Assessment of Cancer Therapy-Bone Pain (FACT-BP)
[30], and the occurrence of SREs and analgesic use were
also collected at these time points. All patients were
advised to take calcium (1,200–1,500 mg/day) and vitamin
D3 (800–1,000 IU/day) while on study.
Endpoints
The primary endpoint was the proportion of patients
maintaining CTx levels within the low risk range
(B600 ng/L) at 48 weeks. However, the primary endpoint
was changed to the proportion of patients coming off study
for any reason at 48 weeks. This was due to evidence that
patients were being removed from treatment before
48 weeks due to SRE and withdrawals. The revised pri-
mary endpoint is therefore the most conservative result.
Secondary endpoints included: frequency of SREs, change
in serum BSAP and change in self-reported pain. Treat-
ment failure was defined as either loss of biochemical
control (defined as confirmed CTx levels[600 ng/L) or an
on-study SRE. Due to CTx variability, if a patient had an
elevation [600 ng/L at the predefined study time points,
then a repeat measure was taken 4 weeks later. If CTx
remained elevated, then that patient was considered a
treatment failure. Some patients did not complete the study
due to withdrawal, progressive disease, or death.
Exploratory analyses assessing the utility of putative
biomarkers of bone turnover or tumour progression as
predictors of treatment failure were also conducted. Bio-
markers of interest with previous evidence of a role in bone
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metastases included: serum-transforming growth factor
(TGF)-b1 [31, 32], activin A [33–36], procollagen type
1 N-terminal propeptide (P1NP) [37–39], bone sialoprotein
(BSP) [40] and urinary NTx levels [41, 42].
Biochemical analysis
Blood was drawn in the morning following an overnight
fast and prior to pamidronate infusion. Samples were
allowed to clot and were centrifuged at 4 C for 10 min at
3,400 RPM. Serum was frozen at -80 C until analysis.
Urine was collected as a second pass, fasting specimen and
frozen at -80 C until analysis. Serum CTx was measured
by chemiluminescence immunoassay using CrossLaps on
an IDS iSYS automated analyzer. Analytical precision
(coefficient of variation, CV) was 11.3 % at 210 ng/L and
6.4 % at 850 ug/L. Serum BSAP was measured by a
chemiluminescence assay, Ostase, on the Beckman
Coulter Unicel DxI. The CV is 7.7 % at 10.0 ug/L and
7.5 % at 44.2 ug/L. 25-hydroxyvitamin D and PTH were
measured by a chemiluminescence assays, on the IDS iSYS
or Beckman Coulter Unicel DxI, respectively.
Alternative biomarkers were measured using specific
enzyme-linked immunosorbant assays (ELISA) in baseline
serum samples for TGF-b1 (Quantikine, R&D Systems,
Minneapolis MN, detection limit 20 pg/ml, interassay
variability *8.3 %), activin A (Quantikine, R&D Systems,
Minneapolis MN, detection limit 4 pg/ml, interassay vari-
ability *5.9 %), P1NP (USCN Life Science Inc., Wuhan
China, detection limit 15 pg/ml, interassay variability
*12 %), and BSP (USCN Life Science Inc., Wuhan
China, detection limit 2 ng/ml, interassay variability
*12 %). Urine NTx levels were measured using the Os-
teomark assay (Alere, Scarborough ME, detection limit 2
nM BCE/mM creatinine, interassay variability 6.9 %). All
samples were measured in duplicate and averaged values
used. When values were below the threshold of detection
for each respective assay, concentrations were assigned as
0.1 units below the sensitivity threshold for purposes of
statistical analysis.
Statistical analysis
Sample size was determined by precision. Prior experience
showed that 72 % of patients treated with 12 weekly
pamidronate maintained their telopeptides in the low risk
range over a 48 week period [20]. Assuming this, 61
patients were needed to estimate this proportion with 95 %
confidence interval width of 20 % (i.e. ±10 %). After
accounting for 10 % drop-out, the required sample size was
68 patients. Patients who came off study for withdrawal,
progressive disease or death were considered treatment
failures for the primary analysis, but a supportive analysis
was performed excluding these patients. For experimental
biomarker analyses, exploratory statistical analysis was
used to compare those eligible for biomarker analysis
versus ineligible using Wilcoxon rank sum tests (continu-
ous variables), Fisher’s exact tests (binary variables) or the
Cochran-Armitage test for trend (ordinal variables).
Spearman correlation coefficients were calculated to
explore for association between clinical factors and base-
line biomarker levels. Logistic regression analyses were
used to evaluate which factors were prognostic for com-
pletion of study therapy or having a SRE. Multivariable
models were constructed using forward stepwise selection
methods. All of the statistical analyses were performed
using SAS software, and were two-sided with a p value of
0.05 or less being considered statistically significant. No
corrections were made for multiple significance testing.
Results
Patient enrolment and baseline characteristics
From October 2010 to September 2011, 84 patients were
screened, with 71 eligible for enrolment (Fig. 1). Baseline
patient characteristics are shown in Table 1. Patients had
bone metastases for a median of 15 months (range 3–106)
and received IV bisphosphonates for a median of
14 months (range 3–106). Of enrolled patients, 17 (24 %)
had a SRE prior to study entry. Thirty-one patients (47 %)
had metastases confined to the skeleton, 29 (41 %) patients
had received one prior line of palliative systemic therapy
while 20 (28 %) had received two lines of systemic therapy
at the time of study entry.
Baseline CTx and BSAP
Median baseline CTx for all patients was 110 ng/L (range
25–850 ng/L, Table 1), and was similar for those patients
eligible for exploratory analysis (Table 1, p = 0.32).
Median baseline BSAP was 9.15 ug/L (range 4.9–1,190 ug/
L, Table 1). There was a statistically significant difference
in the median baseline BSAP levels for patients eligible for
exploratory analysis versus those that were not, with
patients not eligible for exploratory study having higher
median BSAP levels (Table 1, p = 0.007).
Pain scores
Pain at study entry was assessed using two independent
scoring methods, FACT-BP and BPI (assessed as BPI-
severity and BPI-interference). In all cases, pain assess-
ment scores were reflective of low to moderate pain,
indicative of the low-risk patient population enrolled in this
Breast Cancer Res Treat (2014) 144:615–624 617
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study (Table 1). In all cases, no significant difference was
noted in baseline pain scores between those patients eli-
gible for exploratory analysis and those that were not
(Table 1).
Primary analysis
Of the 71 patients enrolled, 43 (61%, 95 % confidence
interval [CI] 48–72 %) completed 48 weeks of de-esca-
lated therapy. Twenty-eight patients did not complete 1
year of de-escalated therapy; 10 patients (14.1 %) came off
study due to biochemical failure (CTx [600 ng/L), 9
(12.7 %) due to the development of a SRE, 6 patients
(8.5 %) were withdrawn from study by their physician due
to disease progression, and 1 patient (1.4 %) due to death
from breast cancer. An additional 2 patients (2.8 %) did
not complete one year of de-escalated therapy due to
withdrawal of consent. We did not observe any bis-
phosphonate-specific toxicities such as renal impairment,
ONJ or atrial fibrillation.
Frequency of SREs
As mentioned, 9 (12.7 %) patients who maintained CTx
\600 ng/L experienced on study SREs. In addition, of the
10 patients who came off study early due to elevated CTx,
4 of these patients subsequently developed a SRE. Thus,
out of the 71 patients enrolled, a total of 13 (17 %) had a
SRE within 1 year of study entry. In contrast, of the 8
screened patients who had signed consent but were ineli-
gible for study entry due to baseline CTx [600 ng/L, 6
(75 %) had a SRE within the year even though they
remained on 3–4 weekly bisphosphonate treatment. Of the
9 patients who withdrew from the study due to progression,
death or patient’s choice, 1 had a SRE within 1 year. This
patient was taken off study by her oncologist due to disease
progression, and her CTx was subsequently found to be
[600 ng/L.
Exploratory analyses of additional putative biomarkers
Of the 71 enrolled patients, 63 (89 %) consented to use of
bio-specimens for exploratory biomarker analyses (urine
NTx, was available from 62 of these 63 patients). Median
levels were: NTx 186 nM BCE/mM creatinine (range
43–1,918); P1NP 34 pg/mL (range 3–125); BSP 44 ng/mL
(range 2–290); TGF-b 17 pg/mL (range 5–29); and activin
A 399 pg/mL (range 187–5,904) (Table 1).
Association between biomarkers and clinical factors
Table 2 shows the Spearman correlation coefficient (q)
estimate measuring association between select clinical
















Abnormal renal function n=5
Reasons for consent failure
Did not want to participate n=14
Fearful of de-escalating treatment n=3
Disease progression or death n=3
Unable to travel n=2
Reasons for not completing study
Elevated CTx n=11
Skeletal related event n=8
Disease progression n=6
Patient choice n=2
Death from disease n=1
Did not consent to 
use of samples for 
research or sample 
unavailable
n=8




Fig. 1 CONSORT diagram
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had only weak to no association with any of the clinical
factors measured. Of the exploratory baseline biomarkers
measured, only baseline BSP and TGF-b showed a mod-
erate association with duration of bone metastases
(Table 2, q = 0.36 and q = -0.40, respectively), while no
associations were noted between any of the other clinical
factors of interest.
Prognostic factors for completion of 1 year of de-
escalated therapy
Baseline vitamin D, NTx, BSP and CTx were all statisti-
cally significant for completion of therapy (Table 3).
Patients with higher serum 25-hydroxyvitamin D (OR 1.20,
95 % CI 1.03–1.39), lower CTx (OR 0.96, 95 % CI
0.93–0.99), lower NTx (OR 0.62, 95 % CI 0.42–0.92) and
lower BSP (OR 0.86, 95 % CI 0.77–0.95) were all more
likely to complete therapy. In multivariable analysis,
vitamin D, NTx and BSP remained associated with likeli-
hood of completion of therapy.
Prognostic factors for occurrence of on study SREs
Prognostic factors for on study SREs were also explored
(Table 4). Baseline CTx or BSAP were not prognostic for
having a SRE on-study (p = 0.69 and p = 0.80, respec-
tively). BPI-severity score was the only factor which was
statistically significantly associated with likelihood
of an on-study SRE (OR 1.15; 95 % CI 1.03–1.28,
p = 0.017).
Table 1 Baseline characteristics





N 71 63 8
Duration of bone metastases
(n = 70), months
Median (range) 15 (3, 106) 15 (3, 106) 14 (9, 59) 0.93
PTH Median (range) 6.5 (1.6, 65) 6.2 (1.6, 65) 7.7 (3, 13) 0.67
Vitamin D Median (range) 93 (5, 203) 93 (5, 203) 90 (49, 138) 0.49
Months, taking Bisphosphonates
prior to starting study
Median (range) 14 (3, 106) 14 (3, 106) 11 (4, 59) 0.54
Baseline CTx Median (range) 110 (25, 850) 110 (25, 740) 235 (25, 850) 0.32
Baseline BSAP (n = 70) Median (range) 9.15 (4.9, 1190.0) 9.05 (4.9, 46.4) 13.85 (8.7, 1190.0) 0.007
FACT-BP subscale Mean (sd) 48.7 (10.8) 48.6 (10.6) 49.5 (12.4) 0.72
BPI-severity (n = 70) Median (range) 3 (0, 26) 3 (0, 26) 1 (0, 13) 0.64
BPI-interference (n = 69) Median (range) 5 (0, 46) 5 (0, 46) 2.5 (0, 28) 0.54
Total number of prior lines of






















































NTx (n = 63) Median (range) 186.1 (43.3, 1918.1) 186.1 (43.3, 1918.1) Not measured –
P1NP (n = 63) Median (range) 33940 (3087, 124933) 33940 (3087, 124933) Not measured –
BSP (n = 63) Median (range) 43.8 (1.99, 290.4) 43.8 (1.99, 290.4) Not measured –
TGF-b (n = 63) Median (range) 16.6 (5.1, 29.4) 16.6 (5.1, 29.4) Not measured –
ActivinA (n = 63) Median (range) 398.6 (187.4, 5904.4) 398.6 (187.4, 5904.4) Not measured –
a Fisher’s exact test comparing C1 versus 0
b Cochran–Armitage test for trend
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Discussion
Increasing interest in de-escalated bone-targeted therapies
has been driven by concerns around the balance between
intravenous bisphosphonate benefit and harm rather than
trying to deliver the optimal frequency of drug based on
individual patients’ needs [3]. De-escalating bone-targeted
therapy in low-risk patients has clear advantages for both
the patients (less visits to the centre for treatment, and
possibly less toxicity), and the health care system (both
through direct and indirect costs) provided that de-escala-
tion is not associated with a worsening of patient outcomes.
Surveys have shown that the concept of de-escalation of
therapy is acceptable to both oncologists [6] and patients
with bone metastases [43].
There is significant heterogeneity in current de-escala-
tion trials in terms of eligibility criteria, bisphosphonate
used (mostly zoledronic acid) and duration of intravenous
bisphosphonate therapy prior to study entry (ranging from
bisphosphonate naı¨ve [22], C3 months [20], to 9–12 [18]
months of prior monthly therapy). Interpretation of study
findings is further confounded by the different outcomes
measured. While some use SREs as the primary endpoint,
others have used biomarkers of bone turnover such as NTx
[22] and CTx [20] as surrogates of SRE risk. Thus, even
with the publication of the ZOOM trial [18] the findings of
a recent systematic review would suggest that clinical
equipoise still exists [44]. Although biomarker-driven
studies have advantages, they should only be used for
planning larger definitive studies [6]. Our current data also
questions their use as prognostic markers of SRE risk. In
patients deemed ‘low-risk’, the most commonly used
markers, namely CTx, NTx, BSAP and P1NP were not
significantly different between patients who experienced
versus those that did not experience on study SREs.
Of the 71 patients who entered the study, 61 % com-
pleted 48 weeks of de-escalated therapy, 14.1 % came off
study early due to elevation of CTx[600 ng/L and 12.7 %
due to on-study SRE. These results are within the 95 % CI
of our previous study, where 72 % of patients treated with
12-weekly pamidronate maintained their telopeptides in the
low risk range. This suggests that serum CTx \600 ng/L
after C3 months of IV bisphosphonate therapy may iden-
tify a patient population at particularly low risk of sub-
sequent SREs, and hence identify likely candidates for
more routine use of de-escalated therapy [20].
Low baseline CTx levels were associated with com-
pleting study in univariate analysis, which is not surprising
given that rises in CTx above 600 ng/L was a mandated
reason to come off study. However, baseline CTx levels in
this low-risk cohort did not correlate with the occurrence of
an on study SRE. This is likely due to the small sample size
in our present study.
The inability of CTx to prognosticate for SRE occur-
rence led us to evaluate other exploratory biomarkers at
baseline to determine whether any of these could be
useful for assisting in determining SRE risk in patients
with CTx levels \600 ng/L. In addition to bone turnover
markers frequently used in other studies (i.e. uNTx and
P1NP), we also examined the levels of TGF-b, activin A
and BSP. TGF-b plays a critical role in osteolytic meta-
static disease [45], and correlates with breast cancer stage
and bone metastasis [31, 32]. Recent studies have also
implicated activin A in metastatic and osteoclastic pro-
cesses [33–35], and plasma levels of activin A are higher
in breast cancer patients with bone metastases as com-
pared to those without, and positively correlate with bone
metastatic burden [36]. Tumour-derived expression of
BSP is also correlated with development of osseous
metastases [40]. Unfortunately, none of the standard





BSAP NTx P1NP BSP TGF-b Activin A
Weight -0.11 -0.06 0.15 0.09 -0.00 0.20 -0.17 0.28 -0.07
Height -0.13 -0.02 -0.02 -0.06 -0.05 -0.11 0.04 -0.23 0.01
BSA -0.13 -0.05 0.12 0.05 -0.02 0.15 -0.11 0.16 -0.03
Duration of bone mets 0.17 0.10 0.04 0.13 0.00 -0.07 0.36 20.40 0.17
PTH -0.26 0.00 -0.01 -0.05 0.15 -0.13 -0.06 -0.02 -0.02
FACT-BP subscale 0.05 -0.00 -0.14 0.14 -0.06 -0.12 -0.25 0.00 -0.12
BPI-severity 0.09 -0.22 -0.06 -0.22 -0.13 0.19 0.03 0.12 -0.02
BPI-interference 0.03 -0.13 0.06 -0.14 0.01 0.27 0.17 0.03 -0.05
Vitamin D – -0.06 -0.19 -0.05 -0.11 0.02 -0.07 -0.09 0.09
Spearman correlation coefficient (q) was used to identify associations between biomarkers and clinical factors. Only two factors were moderately
associated: duration of bone metastases with BSP and TGF-b (highlighted in bold above)
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(CTx, BSAP, NTx or P1NP) nor additional experimental
biomarkers (TGF-b, activin A or BSP) showed any sig-
nificant association with SRE incidence in these low-risk
patients at baseline. However, among the experimental
biomarkers, it should be noted that baseline levels of BSP
were moderately associated with duration of bone
metastases, and were also associated with failure to
complete the study despite the fact that BSP did not reach
statistical significance for an association with incidence
of on-study SRE. Of all the baseline parameters mea-
sured, only baseline pain scores as measured by BPI-
severity was prognostic for increased risk of SRE. This
finding highlights the utility in using pain score assess-
ment tools in these types of studies.
Our study has several limitations, including: use of a
biomarker surrogate for defining a population at low risk of
SREs, a relatively small sample size, the variable duration
of prior 3–4 weekly IV bisphosphonate use and the use of
pamidronate rather than more potent bisphosphonates such
as zoledronic acid. Given our current findings regarding the
lack of association between CTx and SRE incidence in this
low risk cohort, other biomarkers including pain mea-
surement should be considered in these low risk cohorts in
future studies addressing use of de-escalated regimens of
bone-targeting agents. Other potential indicators of bis-
phosphonate efficacy such as control of circulating tumour
cells or levels of cd T-cells should also be further inves-
tigated as the recent literature suggests a potential role in
efficacy of bisphosphonates [46–49]. Our trial and experi-
mental biomarker findings are also limited by the fact that a
small number of clinical events have occurred within the
48-week follow-up of the study. These findings also have
important implications for the design of future studies
addressing these issues in low risk populations, and suggest
that to determine treatment effects on SRE risk, longer
durations of follow-up are required to perform statistically
powered analysis with sufficient numbers of events.
However, it remains possible that changes in biomarker
levels over time may provide better assessment of param-
eters such as SRE risk.





Weight 71 1.00 (0.96, 1.04) 0.93
Height 71 0.96 (0.89, 1.04) 0.30
BSA 71 0.78 (0.05, 12.51) 0.86
Duration of bone metastases 70 1.00 (0.98, 1.03) 0.84
PTH 71 0.95 (0.89, 1.02) 0.17
Vitamin D (/10 units) 71 1.20 (1.03, 1.39) 0.017
FACT-BP Subscale 71 1.01 (0.96, 1.05) 0.82
Baseline CTx (/10 units) 71 0.96 (0.93, 0.99) 0.007
BSAP 70 0.88 (0.77, 1.01) 0.066
NTx (/100 units) 63 0.62 (0.42, 0.92) 0.017
P1NP (/1,000 units) 63 0.99 (0.97, 1.01) 0.41
BSP (/10 units) 63 0.86 (0.77, 0.95) 0.003
TGF-b 63 1.04 (0.95, 1.14) 0.43
Activin A (/100 units) 63 0.96 (0.91, 1.02) 0.19
BPI-severity 70 1.00 (0.92, 1.09) 0.93
BPI-interference 69 1.02 (0.97, 1.06) 0.44
Metastatic disease (bone
only vs bone plus other)
65 1.51 (0.56, 4.06) 0.41
Multivariate analyses
BSP (/10 units) 63 0.82 (0.72, 0.93) 0.003
NTx (/100 units) 63 0.62 (0.39, 0.97) 0.035
Vitamin D (/10 units) 63 1.27 (1.04, 1.54) 0.017
In univariate analyses, vitamin D, CTx, NTx and BSP were all sta-
tistically significant for completion of therapy. In the multivariate
analyses, BSP, NTx and Vitamin D all remained statistically signif-
icant prognostic factors of completion of therapy





Weight 71 1.01 (0.97, 1.06) 0.60
Height 71 1.00 (0.89, 1.12) 0.95
BSA 71 2.57 (0.05, 143.61) 0.65
Duration of bone metastases 70 1.02 (0.99, 1.04) 0.24
PTH 71 1.05 (0.99, 1.12) 0.12
Vitamin D (/10 units) 71 0.97 (0.80, 1.17) 0.75
FACT-BP Subscale 71 0.99 (0.93, 1.05) 0.66
Baseline CTx (/10 units) 71 1.01 (0.97, 1.04) 0.70
BSAP 70 0.99 (0.88, 1.12) 0.85
NTx (/100 units) 63 0.98 (0.77, 1.25) 0.86
P1NP (/1,000 units) 63 1.02 (0.99, 1.04) 0.27
BSP (/10 units) 63 1.07 (0.97, 1.19) 0.19
TGF-b 63 0.88 (0.76, 1.03) 0.11
Activin A (/100 units) 63 0.98 (0.89, 1.08) 0.73
BPI-severity 70 1.15 (1.03, 1.28) 0.017
BPI-interference 69 1.04 (0.99, 1.10) 0.11
Metastatic disease (bone only
vs bone plus other)
65 0.40 (0.09, 1.78) 0.23
Prior SRE (ordinal) 71 1.18 (0.52, 2.70) 0.70
Prior SRE (C1 vs none) 71 1.71 (0.38, 7.75) 0.48
Multivariate analyses
BPI-Severity 70 1.15 (1.03, 1.28) 0.017
Results for the prognostic ability of various factors for a patient
having at least one SRE. BPI-severity score was the only factor sta-
tistically significant in the univariate or multivariate analyses
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In conclusion, reducing the frequency of IV bis-
phosphonate administration could be of benefit to both
patients and the health care system provided it is not
associated with worse patient outcomes. In the current
study we have shown that the majority of patients with a
baseline serum CTx level \600 ng/L after at least
3 months of IV pamidronate have a low risk of SREs with
1 year of de-escalated therapy. However, no association
between CTx levels and on-study SREs was observed in
this low risk cohort, highlighting the need for identification
of markers that are prognostic for SREs. Of all the mea-
sured baseline parameters, only pain as measured by BPI
severity scores was associated with on-study SREs, hence
our data suggest that pain measures may be a promising
candidate marker of SRE risk in these low-risk patients.
The results of our present study along with our previous
pilot randomised study [20] and ZOOM [18] suggest that
de-escalated 12 weekly bisphosphonate treatment will
likely become increasingly used after a limited period of
3–4 weekly treatment. However, there is a need for com-
pletion and analysis of larger more definitive trials,
including those with denosumab, to ensure the safety of
this strategy.
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